Does Retatrutide Cause Muscle Loss? Lean Mass Data and What to Do About It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• Retatrutide is investigational and not FDA-approved. FormBlends does not sell, supply, or formulate retatrutide. This page is educational.
• Some lean mass loss accompanies any significant weight loss, including retatrutide. Phase 2 DEXA substudies showed approximately 80% of weight lost was fat mass and 20% was lean mass at higher doses.
• The 80/20 ratio is comparable to or slightly better than tirzepatide and substantially better than pure caloric restriction (typically 70/30 or worse).
• Lean mass includes muscle, organ tissue, and intracellular water. Contractile muscle loss is smaller than the lean mass figure alone implies.
• Resistance training 2-3x weekly plus 1.2-1.6 g/kg/day protein intake during active weight loss is the evidence-based combination for minimizing muscle loss. Both interventions are necessary; either alone is less effective.

Direct answer

Yes, retatrutide causes some muscle loss, but the loss is proportional to total weight loss and the fat-to-lean ratio is favorable. Phase 2 body composition data showed approximately 80% of weight lost was fat mass and 20% was lean mass at the higher retatrutide doses. The ratio is similar to tirzepatide and bariatric surgery, and better than pure caloric restriction. Lean mass includes muscle plus other tissues, so actual contractile muscle loss is smaller than the lean mass figure suggests. Resistance training and adequate protein intake substantially reduce the muscle loss component.

Table of contents

1. The "muscle loss" question, framed accurately
2. What the phase 2 body composition data actually showed
3. Why lean mass loss is unavoidable with significant weight loss
4. Comparison to tirzepatide, semaglutide, and other interventions
5. The protein evidence
6. The resistance training evidence
7. Special considerations for older adults
8. What we still don't know
9. The contrary view: is muscle loss being overhyped
10. A practical week-by-week training and nutrition framework
11. When to monitor and when to worry
12. FAQ
13. Sources

The "muscle loss" question, framed accurately

"Does retatrutide cause muscle loss?" is two questions blended together.

Question 1: Does any significant weight loss cause some muscle loss? Yes, always. Reducing total body mass while in caloric deficit results in some loss of lean tissue alongside fat tissue. This is a feature of energy balance, not of any specific medication.

Question 2: Does retatrutide cause more muscle loss than other weight loss methods? The answer is "no, and probably less than calorie restriction alone." The fat-to-lean ratio of retatrutide weight loss is favorable.

The combined question often gets answered as if it were question 1 with the implication that retatrutide is uniquely problematic. The accurate answer is that retatrutide produces large weight loss, large weight loss includes some muscle loss, and retatrutide's muscle loss is small relative to its fat loss.

What the phase 2 body composition data actually showed

The phase 2 retatrutide obesity trial (Jastreboff et al., NEJM June 2023) included DEXA (dual-energy X-ray absorptiometry) substudies in a subset of participants to characterize what tissue compartments the weight loss came from. Approximate findings at the 12 mg dose over 48 weeks:

Compartment	Mean change	Proportion of total weight lost
Total body weight	~−24% baseline	100%
Fat mass	~−40-45% of baseline fat mass	~80%
Lean mass	~−8-10% of baseline lean mass	~20%
Visceral adipose tissue	~−50% or greater	(subset of fat mass)
Bone mineral density	Preserved	(not in mass calculation)

The 80/20 fat-to-lean split is favorable. For a hypothetical patient starting at 200 pounds with 35% body fat (70 pounds fat, 130 pounds lean), losing 48 pounds (24%) would mean approximately 38 pounds of fat loss and 10 pounds of lean mass loss. The lean mass loss is real but is a smaller fraction of starting lean mass than fat loss is of starting fat mass.

A note about what "lean mass" includes: DEXA-measured lean mass includes skeletal muscle, organ tissue, connective tissue, and intracellular water. It is not synonymous with contractile muscle mass. A meaningful fraction of "lean mass loss" during weight loss reflects reduced water content and shrinkage of metabolically active organ tissue, not pure muscle loss. The functional impact is therefore smaller than the lean mass figure alone suggests.

Why lean mass loss is unavoidable with significant weight loss

The reason some lean mass loss is unavoidable comes down to basic physiology:

Reason 1: The body sheds tissue proportionally. When body mass decreases, all body compartments shrink to some degree. The body does not selectively reduce only fat without affecting muscle, organs, or water.

Reason 2: Caloric deficit shifts protein balance. When energy intake is below expenditure, protein synthesis decreases unless protein intake and resistance training counter the shift. Even with optimal nutrition and training, some net protein loss occurs.

Reason 3: Hormonal adaptations. Weight loss reduces leptin, increases ghrelin, and shifts thyroid hormone, all of which can modestly accelerate muscle catabolism.

Reason 4: Reduced mechanical loading. Lighter body weight reduces the load on muscles during ordinary activities, which can reduce stimulus for muscle maintenance.

These factors apply to all forms of weight loss. The goal is not zero lean mass loss (impossible) but minimizing it relative to fat loss.

Comparison to tirzepatide, semaglutide, and other interventions

Intervention	Approximate fat-to-lean loss ratio	Source
Calorie restriction alone	~65-75% fat / 25-35% lean	Heymsfield et al. systematic reviews
Calorie restriction plus resistance training	~80-90% fat / 10-20% lean	Stiegler & Cunliffe 2006 meta-analysis
Semaglutide (STEP trials)	~60-65% fat / 35-40% lean (varies by substudy)	Wilding et al. 2021
Tirzepatide (SURMOUNT-1 substudy)	~75-80% fat / 20-25% lean	Look et al. body composition analyses
Retatrutide (phase 2 DEXA)	~80% fat / 20% lean	Jastreboff et al. 2023
Bariatric surgery (gastric sleeve)	~70-75% fat / 25-30% lean	Mundbjerg et al. body composition studies

The pattern: incretin drugs that produce larger weight loss tend to show better fat-to-lean ratios, possibly because the drugs preserve protein metabolism more effectively than pure caloric restriction. Retatrutide's ratio appears similar to or slightly better than tirzepatide.

A caveat about the semaglutide figures: early STEP substudies suggested less favorable lean mass preservation, but methodology and reporting standards vary, and more recent analyses suggest semaglutide may preserve lean mass better than the early reports indicated. Cross-trial comparison of body composition data is approximate.

The protein evidence

The evidence for protein intake during weight loss to preserve lean mass is robust and consistent across populations:

• Standard protein recommendation (0.8 g/kg/day) is inadequate during significant weight loss
• Higher protein intake (1.2-1.6 g/kg/day) is associated with better lean mass preservation in caloric deficit
• The benefit holds across age groups, with older adults possibly benefiting from intake at the upper end of the range
• Protein quality matters: complete proteins with high leucine content (whey, eggs, meat, fish, soy) support muscle protein synthesis more effectively than incomplete or low-leucine sources
• Distribution across the day matters: spreading protein across 3-4 meals at 25-40 g per meal optimizes muscle protein synthesis

For retatrutide patients, the practical challenge is that appetite suppression often reduces overall food intake substantially. A patient eating significantly less may underconsume protein even when motivated to maintain intake. Strategies to address this include:

• Prioritizing protein at every meal (eat protein first, fill in other foods after)
• Whey protein supplementation (20-40 g per serving) to bridge dietary gaps
• Greek yogurt, cottage cheese, eggs, and protein-fortified products as easy options
• Tracking protein intake for the first weeks to verify targets are being met

The resistance training evidence

The evidence for resistance training during weight loss is also robust:

• Resistance training during weight loss preserves significantly more lean mass than weight loss without training
• The effect holds in older adults, women, and patients with obesity
• Two to three sessions per week is sufficient for most patients; more is generally not better in this context
• Compound movements (squat, deadlift, bench press, row variants) produce more muscle stimulus per unit time than isolation work
• Moderate-to-high intensity (loads requiring 6-15 repetitions to near-failure) is more effective than light loads
• Beginners can use bodyweight or machine-based work and progress as strength develops

The combination of resistance training plus adequate protein outperforms either intervention alone. Patients who do only resistance training without sufficient protein still lose some muscle. Patients who eat sufficient protein without training lose less than restricted-protein patients but more than trained patients.

For retatrutide patients specifically, training during the active weight loss phase (months 1-12) is more important than training after weight stabilizes. The metabolic stress of active weight loss is when muscle is most vulnerable. Patients who establish training habits early have better outcomes.

Special considerations for older adults

Muscle preservation matters more in older adults because of pre-existing sarcopenia (age-related muscle loss). Considerations:

• Baseline muscle mass is lower in older adults, so the same absolute lean mass loss represents a larger fraction of starting muscle
• Older adults have anabolic resistance: protein and resistance training produce smaller muscle responses than in younger adults
• Higher protein intake (toward 1.6 g/kg/day or even higher) may be appropriate
• Resistance training is even more important; the metabolic and functional consequences of muscle loss are larger
• Pre-existing functional limitations may make compound movements challenging; machine-based or supervised programs may be necessary

The FRAIL framework (Fatigue, Resistance, Ambulation, Illness, Loss of weight) is sometimes used to identify older adults at higher risk of poor outcomes during medical weight loss. Patients identified as pre-frail or frail may need closer monitoring or modified treatment plans.

What we still don't know

The body composition story for retatrutide has gaps that future trials will need to address:

• Long-term body composition trajectories. Phase 2 data covered 48 weeks. Multi-year body composition is not characterized.
• Body composition during withdrawal. When patients stop retatrutide, weight regain typically includes more fat than lean. The pattern of regain is not yet published for retatrutide.
• Effects of intentional muscle-building during therapy. Can patients on retatrutide build muscle while losing fat with optimal training and nutrition? The biological possibility exists but trial data is limited.
• Sex differences. Men and women have different baseline body compositions and may respond differently. Phase 2 included both but did not characterize sex differences in body composition.
• Strength and function metrics. DEXA measures tissue mass. It does not directly measure strength, power, or functional capacity. Patients can lose lean mass without losing functional strength if remaining muscle is well-maintained.
• Effects in athletes or highly active populations. All trials enrolled patients with obesity. Effects in lean, active individuals are not characterized.

The contrary view: is muscle loss being overhyped

The "muscle loss" narrative around incretin drugs has become loud, sometimes louder than the evidence supports. A skeptical view of the muscle loss panic:

Argument 1: The ratio matters more than the absolute number. Patients hear "you lose 20% lean mass" and imagine catastrophic muscle wasting. The reality is that 80% of weight loss is fat, lean mass loss is partly water and organ tissue, and contractile muscle loss is a smaller subset. The framing matters.

Argument 2: Strength and function often improve. Despite some lean mass loss, patients on incretin drugs frequently report improved exercise capacity, easier movement, and increased strength relative to their body weight. The clinical experience often outpaces the body composition concerns.

Argument 3: Metabolic gains outweigh modest muscle loss. A patient who loses 50 pounds and 10 pounds of lean mass has dramatically improved cardiovascular risk, diabetes risk, joint loading, and quality of life. Anchoring on the 10 pounds of lean mass while ignoring the metabolic gain misallocates attention.

Argument 4: Compared to alternatives, the ratio is favorable. Patients with significant obesity who do not treat it often lose lean mass to sarcopenic obesity over time. The "do nothing" comparator is not zero lean mass loss; it is gradual lean mass decline plus continued fat gain.

The counter: Muscle loss matters more for some patients (older adults, patients with pre-existing sarcopenia, athletes). Dismissing the concern entirely is also a mistake. The appropriate position is taking the concern seriously enough to act on it (protein, resistance training) without letting it dominate the decision-making about therapy.

A practical week-by-week training and nutrition framework

For a hypothetical retatrutide patient (commercial product not yet available, framework applies to other incretin therapy):

Timeframe	Protein target	Resistance training	Additional priorities
Pre-treatment	Establish 1.2 g/kg baseline	2x/week familiarization with key movements	Baseline DEXA if available; baseline labs (ferritin, B12, vit D)
Weeks 1-4 (titration)	1.2-1.4 g/kg	2x/week, moderate effort	Manage GI side effects; protein supplement bridge if intake drops
Weeks 5-12 (early active loss)	1.4-1.6 g/kg	2-3x/week, progressive load	Track protein for at least one week; verify hitting targets
Months 4-9 (active loss)	1.4-1.6 g/kg	2-3x/week, progress strength	Reassess body composition at 6 months if possible
Months 10-12 (approaching maintenance)	1.4-1.6 g/kg	2-3x/week, maintenance or strength focus	Adjust intake as weight stabilizes
Maintenance	1.2-1.6 g/kg	2x/week sustained	Long-term habit consolidation

When to monitor and when to worry

Most retatrutide patients will not need formal monitoring of lean mass. Reasons to seek more rigorous tracking:

• Older adult with concerns about pre-existing sarcopenia
• Athlete or highly active person whose function depends on muscle mass
• History of eating disorder or severely restricted intake
• Significant pre-existing functional limitations
• Subjective sense of significant weakness or strength loss
• Difficulty performing previously easy daily activities

If monitoring is warranted, options include:

• DEXA scan every 6-12 months (most accurate, modest cost, requires access to a DEXA facility)
• Bioelectrical impedance analysis (less accurate but accessible, useful for trends)
• Functional measures: grip strength, sit-to-stand counts, walking speed
• Strength tracking through resistance training log: are loads stable or progressing?

Concerning signs that warrant clinical attention:

• Rapid strength loss despite training and adequate protein
• New difficulty with daily activities (stairs, carrying groceries)
• Falls or near-falls
• Severe fatigue out of proportion to expected energy reduction

FAQ

Does retatrutide cause muscle loss? Yes, like any significant weight loss. About 20% of weight lost was lean mass in phase 2 at higher doses. Resistance training and protein reduce the loss.

How much muscle do you lose on retatrutide? Roughly 20% of total weight lost, of which only a subset is actual contractile muscle. The remainder is water and organ tissue.

Is retatrutide worse for muscle than tirzepatide? Phase 2 data suggests similar or slightly better lean mass preservation with retatrutide. Direct head-to-head data does not exist.

How can I prevent muscle loss on retatrutide? Resistance training 2-3x weekly plus 1.2-1.6 g/kg/day protein intake during active weight loss.

Will I lose muscle without lifting weights? Yes, more than you would with training. Resistance training is the single most important muscle preservation intervention.

Is lean mass loss the same as muscle loss? No. Lean mass includes muscle plus organ tissue, connective tissue, and water. Actual muscle loss is a subset of lean mass loss.

Can I build muscle while on retatrutide? Possibly, especially in untrained individuals or with optimal training and protein. The biological possibility exists; trial data is limited.

How much protein should I eat? 1.2 to 1.6 g/kg body weight per day during active weight loss. Older adults may benefit from the upper end of the range.

What if I have a low appetite from retatrutide? Prioritize protein at every meal. Use whey or other protein supplements to bridge intake gaps. Smaller frequent meals may work better than large infrequent ones.

Will my strength decline on retatrutide? Without intervention, possibly. With resistance training and adequate protein, strength can be maintained or improved.

Is muscle loss permanent? Generally no. Lean mass can be rebuilt after weight stabilizes with continued training and protein.

Should I get a DEXA scan before starting retatrutide? Optional but informative. A baseline DEXA allows direct measurement of changes over time. Not strictly necessary if you are not in a high-risk group for muscle loss concerns.

Related guides

• Retatrutide and Body Composition Lean Mass
• Retatrutide and Muscle Loss: What Trial Data Shows
• Does Retatrutide Cause Hair Loss? A Look at the Phase 2 Data and the Mechanism
• Retatrutide and Muscle Loss: What to Expect and How to Manage
• Muscle Loss Prevention on Retatrutide
• Does Retatrutide Cause Hair Loss?

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. June 2023.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
4. Look AHEAD Research Group. Body composition outcomes in intensive lifestyle interventions for adults with type 2 diabetes. Obesity. 2019.
5. Stiegler P, Cunliffe A. The Role of Diet and Exercise for the Maintenance of Fat-Free Mass and Resting Metabolic Rate During Weight Loss. Sports Medicine. 2006.
6. Heymsfield SB et al. Body composition phenotypes in pathways to obesity and the metabolic syndrome. International Journal of Obesity. 2011.
7. Phillips SM et al. Protein "requirements" beyond the RDA: implications for optimizing health. Applied Physiology, Nutrition, and Metabolism. 2016.
8. Hector AJ, Phillips SM. Protein Recommendations for Weight Loss in Elite Athletes: A Focus on Body Composition and Performance. International Journal of Sport Nutrition and Exercise Metabolism. 2018.
9. Cruz-Jentoft AJ et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019.
10. Wolfe RR. The underappreciated role of muscle in health and disease. American Journal of Clinical Nutrition. 2006.
11. Endocrine Society. Clinical Guidance on Investigational Incretin Therapies. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed clinicians and U.S. state-licensed pharmacies. FormBlends does not manufacture, prescribe, or dispense medication. FormBlends does not sell, supply, or formulate retatrutide. Retatrutide is investigational and not FDA-approved as of May 2026.

Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide available through FormBlends-connected 503A state-licensed compounding pharmacies are not FDA-approved drugs. Body composition outcomes on these compounded preparations are expected to follow patterns similar to brand-name semaglutide and tirzepatide, with significant individual variation. Retatrutide is not offered as a compounded medication through FormBlends.

Results Disclaimer. Body composition figures cited reflect trial averages and may not predict individual outcomes. Protein intake recommendations are based on aggregated evidence and may need individualization for patients with kidney disease, hepatic disease, or other conditions affecting protein metabolism. Resistance training recommendations assume general medical clearance for exercise.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Retatrutide is the international nonproprietary name for an Eli Lilly investigational compound. FormBlends is not affiliated with Eli Lilly, Novo Nordisk, the Endocrine Society, or any cited research sponsor.